Protective effect of probucol on alloxan diabetes in rats. With special reference to alloxan dose-response.:with Special Referenceto Alloxan Dose-Response

概要

論文の詳細を見る
In order to examine the effect of probucol, a powerful free radical scavenger, on alloxan diabetes, 20 to 50 mg/kg of alloxan was injected into male Wistar rats with or without 2 weeks of pretreatment with probucol (1% in standard diet). Twenty-four hours after injection of 20, 30 and 40 mg/kg of alloxan, there were no significant differences in blood glucose levels between the rats pretreated with probucol (group PA) and the untreated rats (group A). On the other hand, group PA had significantly lower blood glucose levels than group A at the 50 mg/kg of alloxan. There was no difference in the plasma insulin levels of the two groups at this dose of alloxan, but serum enzymes, such as GOT and LDH, were lower in group PA than in group A. There were no significant differences however, in GPT, blood urea nitrogen, creatinine, uric acid or triglyceride in the two groups at any dose. Group PA had lower plasma cholesterol levels than group A. Thus, it appears that the multiple organ toxicity (including pancreatic β-cells) of alloxan was reduced by pretreatment with probucol, although the effect was incomplete. It is possible that probucol prevents accumulation of free radicals in the target cells of alloxan. Since accumulation of free radicals can be an initial step in pancreatic β-cell damage in animal models of Type I diabetes, probucol can be a useful drug for the prevention of Type I diabetes.
一般社団法人日本糖尿病学会の論文